New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareIpamorelin vs Pancragen

Ipamorelin vs Pancragen

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
Ipamorelin
Anti-Aging & Longevity
Pancragen
Summary
Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Half-Life
2 hours
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
100–300 mcg
10 mg per day
Frequency
Once to twice daily
Daily for 10–30 days
Key Benefits
  • Increases lean muscle mass
  • Enhances fat loss
  • Improves recovery time
  • Strengthens bones and joints
  • Better sleep quality and REM sleep
  • Enhanced skin elasticity
  • Minimal impact on hunger or cortisol
  • No cortisol or prolactin spike
  • Clean GH release suitable for long-term protocols
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
Side Effects
  • Injection site irritation
  • Temporary water retention (mild)
  • Possible hunger increase (milder than GHRP-6)
  • Numbness or tingling in extremities (rare)
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
Stacks With